Evaluating Sintilimab Combined With Chemotherapy and Adaptive Radiotherapy for Stage III Non-small Cell Lung Cancer
Led by The Third Xiangya Hospital of Central South University · Updated on 2026-09-02
35
Participants Needed
4
Research Sites
91 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of combining Sintilimab with platinum-doublet chemotherapy and an adaptive radiotherapy strategy for patients with Stage III non-small cell lung cancer NSCLC. This phase 2 trial focuses on patients who cannot undergo surgery and have no sensitive driver gene mutations, aiming to improve treatment outcomes in this group.
Participants receive two cycles of Sintilimab and platinum-based chemotherapy followed by two more courses combined with adaptive radiotherapy. Chemotherapy drugs include Cisplatin or Carboplatin, with Paclitaxel or Pemetrexed depending on cancer type. The adaptive radiotherapy dosing is tailored to minimize lung damage while targeting tumors effectively.
Throughout the study, participants undergo regular assessments including tumor measurements, organ function tests, and monitoring for side effects. The primary measure is progression-free survival over 28 months, with additional evaluations of response rates, survival, and safety. The trial lasts until 28 months post-treatment start, with ongoing monitoring for disease control and adverse events.
CONDITIONS
Brief Title
The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Research Team
X
XueWen Liu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Single-arm, multicentre phase II trial of sintilimab plus platinum-based doublet chemotherapy followed by adaptive radiotherapy strategy for patients with unresectable stage III non-small-cell lung cancer in China: the ART-LUNG 01 study protocol.